Valeritas Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Valeritas's estimated annual revenue is currently $26.4M per year.
- Valeritas received $23.7M in venture funding in May 2016.
- Valeritas's estimated revenue per employee is $145,044
- Valeritas's total funding is $333.9M.
- Valeritas has 182 Employees.
- Valeritas grew their employee count by 21% last year.
- Valeritas currently has 4 job openings.
|Scott Huie||VP, RA/QA and Compliance|
|Matthew Nguyen||SVP Commercial|
|Chris Gregory||VP of R&D|
|Christopher Dunn||Area Business Director - Central and West US|
|Carla Nikkel||Senior Director Medical Affairs|
|Scott Abbott||Director, New Product Commercialization|
|Jim Slevin||Senior Director, Account Management|
|Bardsson Larrabee||Director of Marketing|
|Doug Winkler||National Account Director|
|Mona Gorman||Director of Training & Leadership Development|
What Is Valeritas?
We are a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. We designed our first commercialized product, the V-Go Wearable Insulin Delivery Device, or V-Go, to help patients with Type 2 diabetes who require insulin to achieve and maintain their target blood glucose goals. V-Go is indicated for continuous subcutaneous infusion of insulin over 24 hours at preset rates and on-demand bolus dosing in two-unit increments in adult patients requiring insulin. V-Go is a small, discreet and easy-to-use disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery by using one type of insulin (fast-acting) at a continuous preset (background) basal rate over a 24-hour period and provides on-demand bolus dosing for meals and snacks. In numerous real-world analyses V-Go has consistently shown to lower A1C's with less insulin. The discreet and convenient basal-bolus insulin delivery method provided by V-Go empowers patients to simplify their insulin management thereby mitigating the need to plan their daily routine around multiple daily injections. V-Go is cleared for use in the United States and the E.U. is commercially available in the United States.keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|ACTEON North Am...||$22.8M||97||8%||N/A|
|Topcon Medical ...||$64M||273||5%||N/A|
Clinical Trial Evaluating Delivery of Regular Human Insulin vs. Rapid Acting Insulin Delivered by Valeritas' V-Go® Meets Primary A1c Endpoint.
BRIDGEWATER, N.J., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and ...
BRIDGEWATER, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and ...
|2011-09-13||$150.0M||C||Welsh Carson Anderson and Stow||Article|
|2013-06-05||$100.0M||Undisclosed||Capital Royalty L P||Article|
Valeritas Executive Hires
|2006-09-14||John E. Timberlake||EVP||Article|
|2006-11-10||Poul Strange||Chf Scientific Officer||Article|
|2006-12-26||Tara Charvat||VP Mktg/Mktg Operations||Article|
|2007-06-20||Mike Stout||VP Sales/SalesOperations||Article|
|2010-03-18||James E. Dentzer||CFO||Article|
|2016-02-26||John Timberlake||Interim CEO||Article|
|2016-08-17||Erick J. Lucera||CFO||Article|
|2018-01-10||Joseph Saldanha||Chief Business Officer||Article|